Washington, DC: National Academies Press (2000)
Some Cigna plans require step therapy with Wegovy or an older agent before approving Zepbound
In addition, prominent market players have adopted several growth strategies in the clinical trials market in recent years
Recent Articles The Return of 503B Compounding of GLP-1 Medications Over the last two years, the surging demand for GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) has created both clinical October 23, 2025 FDA Issues Import Alert on GLP-1s Following Launch of Green List On September 19, 2025, the FDA issued Import Alert 66-80, which authorizes field staff to detain without physical examination shipments of GLP-1 active pharmaceutical ingredients October 1, 2025 Thea GLP-1 Crossroads: What Pharmacies Must Know About Compliance, Coverage, and the Future of Access The surge of GLP-1 medications, from semaglutide products such as Ozempic and Wegovy to new therapies in the pipeline, has created one of September 4, 2025 Recent Webinars Navigating GLP-1 Compounding Webinar Series Stay ahead of the curve with our webinar series navigating the evolving regulatory landscape for GLP-1 compounding
People with severe liver or kidney conditions must exercise caution while using any supplement
